Company intelligence
MediWound
Next-generation enzymatic therapeutics for non-surgical tissue repair
Pharmaceutical Manufacturing
Yavne, IL
122 employees
Founded 2001
1 public signals
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.
Verified activity
Signals from MediWound
1 published signal